The 30 Best Targeted cancer therapy in South San Francisco, California

Tarceva is a health institution located at 1 DNA Way in South San Francisco, California, United States. We are dedicated to making a difference in the lives of our patients, employees, and communities. Our commitment to diversity and inclusion drives us to create tangible change that will have a lasting impact. Join us in our mission to improve healthcare and make a positive difference in the world.

Genentech BioOncology is a leading institution in the field of healthcare, specializing in oncology research and treatment. Located at 1 DNA Way in South San Francisco, California, United States, Genentech BioOncology is dedicated to advancing the understanding and treatment of cancer. With a focus on innovative therapies and personalized medicine, the institution is committed to improving outcomes for cancer patients worldwide. Through cutting-edge research and collaboration with healthcare professionals, Genentech BioOncology is at the forefront of revolutionizing cancer care.

Oncology Therapeutic Networking is a leading health institution located at 395 Oyster Point Boulevard in South San Francisco, California, United States. Specializing in oncology treatments, this institution offers cutting-edge therapies, personalized care, and a network of medical professionals dedicated to providing the best possible outcomes for cancer patients. With a focus on collaboration and innovation, Oncology Therapeutic Networking is committed to advancing the field of oncology and providing hope and support to those affected by cancer.

Dr. Hyunseok Kang is a medical oncologist and specialized cancer researcher located at 1600 Divisadero Street in San Francisco, California. Dr. Kang, also known as Hyu, specializes in treating adults with head and neck cancers using conventional chemotherapy, targeted therapy, and immunotherapy. He is actively involved in researching new therapies for head and neck cancers through clinical trials, focusing on improving the efficacy of immune checkpoint inhibitors and developing targeted approaches for rare cancers of the head and neck. Dr. Kang earned his medical degree at Yonsei University College of Medicine in Seoul, South Korea, and completed his residency and fellowship in internal medicine, hematology, and medical oncology in the United States. He is a fellow of the American College of Physicians and a member of several oncology and cancer research organizations. Prior to joining UCSF Health, Dr. Kang worked at the Johns Hopkins Hospital and served as an assistant professor of oncology at the Johns Hopkins University School of Medicine. He is currently involved in various research studies aimed at improving cancer treatment outcomes, including studies on adenoid cystic carcinoma, advanced solid tumors, and squamous cell carcinoma of the head and neck.

Loxo Oncology, Inc. is a biopharmaceutical company located at 201 Haskins Way in South San Francisco, California, United States. Specializing in the development of targeted cancer therapies, Loxo Oncology is dedicated to advancing precision medicine to improve outcomes for patients with genetically defined cancers. With a focus on innovative research and a commitment to personalized medicine, Loxo Oncology is at the forefront of the fight against cancer.